(Q35544070)

8 August 2017

1 reference

reason for preferred rank

title

Peginterferon vs. standard interferon in the treatment of chronic hepatitis C (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01747.X

14 March 2024

Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510739

14 March 2024

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510739

14 March 2024

author name string

A. Zaman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510739

14 March 2024

M. B. Fennerty

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510739

14 March 2024

E. B. Keeffe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510739

14 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2003.01747.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14510739

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01747.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01747.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01747.x

14 March 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01747.X

Alimentary Pharmacology & Therapeutics

14 March 2024

published in

1 reference

8 August 2017

volume

18

1 reference

8 August 2017

issue

7

1 reference

8 August 2017

page(s)

661-670

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01747.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01747.X

14 March 2024

Identifiers

1 reference

8 August 2017

1 reference